View in browser

May 2023

A warm welcome to the latest CIC newsletter. In this edition we are delighted to update you on some new investments, portfolio developments and new team members.

The CIC team is passionate about science and technology and realising its commercial potential. We support the most promising entrepreneurs to achieve their vision. All of our investments have the potential to drive significant societal impact. This led to our new tagline 'Because Science and People Matter'.

We are also excited to launch our new website, which we hope you find informative. If you have any feedback, please do let us know.

Andrew Williamson

Managing Partner

AT A GLANCE

NEW INVESTMENTS

We have added two new companies to our portfolio.

We co-led the $28m Series A funding round of Mosaic Therapeutics, an oncology therapeutics company dedicated to resolving cancer’s complexity to power new treatments for patients. The investment will be used to further advance targeted oncology therapies for biomarker-stratified patient populations, progressing its lead programmes through preclinical development to IND-enabling studies.

We also participated in the €72m Series A financing of Complement Therapeutics, a preclinical stage biotechnology company with research laboratories in Stevenage, UK, which is developing novel therapeutics for the treatment of complement-mediated diseases - chronic, complex, and progressive diseases that occur when the human body’s immune system becomes overly active.

CIC News

40 years of VC: Where does Europe’s biggest VC hub stand today?

UK’s Cambridge tries to catch up with younger, innovative peer

University research ‘spinouts’ to be reviewed by UK government

SUSTAINABLE SEMICONDUCTOR MANUFACTURING

Substituting silicon chips with flexible semiconductors can vastly reduce the environmental impact of smart products.

A new white paper from Pragmatic looks at the emissions profile of semiconductor manufacturing, and its impact on the carbon footprint of smart products.